DermTech Announces Appointment of Kevin Sun as Chief Financial Officer
September 16 2019 - 4:30PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “company”), a
global leader in precision dermatology enabled by a non-invasive
skin genomics platform, announced today that Kevin Sun has been
appointed as Chief Financial Officer, Treasurer and Secretary. Mr.
Sun will serve on the executive leadership team and lead DermTech’s
finance, investor relations, human resources and information
technology functions.
Mr. Sun brings almost two decades of corporate finance
experience, including debt and equity financings, acquisitions,
commercial product launches and infrastructure scaling and
expansion projects mostly in the medical device and diagnostic
industries. From 2008 to 2018, Mr. Sun served in various executive
and management roles for DexCom, Inc., a NASDAQ-listed medical
device company, including most recently as Vice President,
Corporate Controller and Treasury, Interim Chief Financial Officer,
and Vice President, Finance, and had key roles during a phase of
significant growth and expansion as DexCom created the category to
ultimately become the global leader in real-time continuous glucose
monitoring devices. During Mr. Sun’s tenure as Interim Chief
Financial Officer, DexCom raised $400 million in convertible debt.
Prior to DexCom, Mr. Sun held various roles of increasing
responsibility at Biosite Incorporated, a NASDAQ-listed leader in
rapid point of care diagnostics. Mr. Sun holds a B.S. in Business
with a dual major in Accounting and Finance, a minor in Psychology,
a Masters in Strategic Management and an MBA from the Kelley School
of Business at Indiana University.
Kevin Sun commented, “DermTech offers a compelling value
proposition to patients, clinicians and payors with solutions that
enable the earliest detection of skin cancer using a non-invasive,
highly accurate and low-cost method. I’m excited to be part of a
fantastic team and I look forward to helping scale the company to
bring this technology to the forefront of dermatology.”
The company also announced that its founding Chief Financial
Officer, Steven Kemper, will be retiring in October 2019, after
almost six years leading the finance and accounting efforts at
DermTech. “It has been an incredible opportunity to work with Dr.
Dobak these last six years to help build DermTech from a few
scientists with a great technology platform into the leading
genomic skin cancer diagnostic company in the U.S. I remain a huge
supporter of the company and its clear benefit for physicians and
patients,” said Mr. Kemper.
John Dobak, M.D., the CEO of DermTech, commented, “I am
extremely excited to have Kevin join our team. His experiences
helping to drive the tremendous growth at DexCom will serve
DermTech well as we scale up and drive toward our own similar
growth goals. I would also like to thank Steve for his hard work
and dedication to DermTech. He was an integral part of DermTech’s
success to date and I wish him the best in his retirement.”
About DermTech:
DermTech is a leader in the new category of medicine, precision
dermatology. DermTech’s mission is to transform the practice of
dermatology through more accurate diagnosis and treatment, and the
elimination of unnecessary surgery, leading to improved patient
care and lower costs. DermTech provides genomic analysis of skin
samples collected non-invasively using an adhesive patch rather
than a scalpel. DermTech markets and develops products that
facilitate the early detection of skin cancers, assess inflammatory
diseases, and customize drug treatments. For additional information
on DermTech, please visit DermTech’s investor relations site at:
www.DermTech.com.
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of the company may differ from their
actual results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to the future growth and
scaling of the business of the company. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from the expected
results. Most of these factors are outside of the control of
DermTech and are difficult to predict. Factors that may cause such
differences include, but are not limited to: (1) the outcome of any
legal proceedings that may be instituted against the company; (2)
the inability to maintain the listing of the company’s securities
on Nasdaq; (3) the ability to recognize the anticipated benefits of
the recently completed business combination, which may be affected
by, among other things, competition, the ability of the company to
grow and manage growth profitably and retain its key employees; (4)
costs related to or resulting from the business combination; (5)
changes in applicable laws or regulations; (6) the demand for the
company’s services together with the possibility that the company
may be adversely affected by other economic, business, and/or
competitive factors; and (7) other risks and uncertainties included
in (x) the “Risk Factors” sections of the Registration Statement on
Form S-4 filed with the SEC by the company, and (y) other documents
filed or to be filed with the SEC by the company. DermTech cautions
that the foregoing list of factors is not exclusive. You should not
place undue reliance upon any forward-looking statements, which
speak only as of the date made. DermTech does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in their expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190916005871/en/
Sarah Dion, VP Marketing sdion@dermtech.com (858) 450-4222
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2023 to Apr 2024